Optinose Reports Third Quarter 2022 Financial Results and Operational Updates

Go back to Optinose Reports Third Quarter 2022 Financial Results and Operational Updates

Optinose (OPTN) PT Lowered to $5 at BMO Capital

November 11, 2022 8:53 AM EST

BMO Capital analyst Gary Nachman lowered the price target on Optinose (NASDAQ: OPTN) to $5.00 (from $6.00) while maintaining an Outperform rating.

The analyst commented, "3Q Xhance rev. missed by $3mm, but OPTN managed expenses offsetting that for in-line EPS. Xhance is facing some NT... More

OptiNose (OPTN) Tops Q3 EPS by 1c

November 10, 2022 7:56 AM EST

OptiNose (NASDAQ: OPTN) reported Q3 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $20.1 million versus the consensus estimate of $23.55 million.

GUIDANCE:

OptiNose sees Q4 2022 revenue of $74-78 million.

For earnings history and earnings-related data on OptiNose (OPTN) click here.

... More